Trending

stem cell therapy

Vertex looks beyond cystic fibrosis with $950m Semma buy

Vertex looks beyond cystic fibrosis with $950m Semma buy

Vertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including

X

Vertex looks beyond cystic fibrosis with $950m Semma buy

https://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/

Mesoblast poised to file cell therapy for GVHD in US

Mesoblast poised to file cell therapy for GVHD in US

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute

X

Mesoblast poised to file cell therapy for GVHD in US

https://pharmaphorum.com/news/mesoblast-cell-therapy-gvhd-fda/

First ever ‘off the shelf’ stem cell therapy nears European approval

First ever ‘off the shelf’ stem cell therapy nears European approval

Alofisel recommended for complex perianal fistulas in Crohn’s disease

X

First ever ‘off the shelf’ stem cell therapy nears European approval

https://pharmaphorum.com/news/tigenixtakeda-stem-cell-therapy-backed-eu-regulators/

FDA cracks down on bogus cell therapy firms

FDA cracks down on bogus cell therapy firms

The FDA’s commissioner Scott Gottlieb has pledged to crack down on “unscrupulous actors” attempting to treat patients with

X

FDA cracks down on bogus cell therapy firms

https://pharmaphorum.com/news/fda-crack-bogus-cell-therapy-firms/

J&J to work with Orthocell on new regenerative stem cell therapy

J&J to work with Orthocell on new regenerative stem cell therapy

Multi-centre trial of Ortho-ATI technology planned for early 2017.

X

J&J to work with Orthocell on new regenerative stem cell therapy

https://pharmaphorum.com/news/jj-work-orthocell-new-regenerative-stem-cell-therapy/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com